(Circulation. 2001;103:2048.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
From Internal Medicine II, Nagoya University School of Medicine (T.K., K.O., T.T., T. Suzuki, H.K., H. Matsui, T.H.), Nagoya, Japan; and Department of Cardiology (T. Sone, J.K., H.T., H. Mukawa), Ogaki Municipal Hospital, Ogaki, Japan.
BackgroundHyperhomocysteinemia
has been identified as an independent risk factor for coronary
artery disease. Recent studies have shown that a common mutation
(nucleotide 677 C
T) in the
methylenetetrahydrofolate reductase
(MTHFR) gene may contribute to mild hyperhomocysteinemia and,
therefore, to the incidence of coronary artery disease. No
information exists, however, regarding the association between the
mutation of the MTHFR gene or plasma homocysteine levels and
morphological analysis of coronary
atherosclerosis using intravascular
ultrasound.
Methods and ResultsTo examine the potential influence of MTHFR genotype and homocysteine on coronary arteries morphologically, we screened 62 patients with 65 lesions that were treated with 93 Palmaz-Schatz stents. The plasma homocysteine levels in the patients with the TT genotype were not significantly higher than those in the patients with non-TT (CC+CT) genotypes (13.1±5.5 versus 11.5±3.1 mmol/L, P=0.16). Angiographic analysis showed that the percent diameter stenosis in the patients with the TT genotype was significantly greater than that in those with non-TT genotypes (43.7±17.8% versus 29.0±22.0%, P=0.015). Intravascular ultrasound analysis showed that the TT genotype was significantly associated with greater intimal hyperplasia area (5.70±1.94 versus 3.72±1.38 mm2, P=0.001). In multiple stepwise regression analysis, the number of the T alleles was the only independent predictor of intimal hyperplasia after intervention (r2=0.21, P=0.004).
ConclusionsThe homozygous mutant genotype of the MTHFR gene may increase the risk of in-stent restenosis more than does the normal homozygous or heterozygous genotype.
Key Words: angiography genes restenosis stents ultrasonics
This article has been cited by other articles:
![]() |
G. De Luca, H. Suryapranata, G. Gregorio, H. Lange, and M. Chiariello Homocysteine and Its Effects on In-Stent Restenosis Circulation, November 8, 2005; 112(19): e307 - e311. [Full Text] [PDF] |
||||
![]() |
H. Lange, H. Suryapranata, G. De Luca, C. Borner, J. Dille, K. Kallmayer, M. N. Pasalary, E. Scherer, and J.-H. E. Dambrink Folate Therapy and In-Stent Restenosis after Coronary Stenting N. Engl. J. Med., June 24, 2004; 350(26): 2673 - 2681. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Koch, G. Ndrepepa, J. Mehilli, S. Braun, M. Burghartz, H. Lengnick, K. Kolling, A. Schomig, and A. Kastrati Homocysteine Status and Polymorphisms of Methylenetetrahydrofolate Reductase Are Not Associated With Restenosis After Stenting in Coronary Arteries Arterioscler. Thromb. Vasc. Biol., December 1, 2003; 23(12): 2229 - 2234. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Schnyder, Y. Flammer, M. Roffi, R. Pin, and O. M. Hess Plasma homocysteine levels and late outcome after coronary angioplasty J. Am. Coll. Cardiol., November 20, 2002; 40(10): 1769 - 1776. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C. Lowe, S. N. Oesterle, and L. M. Khachigian Coronary in-stent restenosis: Current status and future strategies J. Am. Coll. Cardiol., January 16, 2002; 39(2): 183 - 193. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |